Efflux

Spero Therapeutics to Present Data at IDWeek 2021

Retrieved on: 
Thursday, September 16, 2021
Tebipenem, Medicare, HBR, Therapy, Pyelonephritis, Escherichia coli, Epidemiology, Infection, Pseudomonas aeruginosa, Doctor of Philosophy, Patient, Drug of last resort, Molecular epidemiology, Cutis marmorata telangiectatica congenita, Nasdaq, Adult, IDSA, Outer membrane porin D, Degenerative disease, MDR, AMPC, Efflux, UTI, Collection, Infectious Diseases Society of America, AP, GLOBE, NTM, Spero, Health care, Research, Time-invariant system, Urinary tract infection, Pharmaceutical industry, Medical device, Animal, Vaccine, Medical imaging

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.
  • Title: Molecular epidemiology of Escherichia coli causingurinary tract infectionsin the United States and in vitro activity of tebipenem, includingagainststrain lineage and resistant subsets (2018-2020)
    12.
  • Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations
    14.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at BTIG's Virtual Biotechnology Conference 2021

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Branches of biology, Natural sciences, Pharmaceutical industry, Biotechnology, Cytokines, Inflammasome, Biopharmaceutical, Medication, Efflux, Kidney

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.

Key Points: 
  • To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.
  • Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephe...

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium July 21-23, 2021

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Pharmaceutical industry, Natural sciences, Health sciences, Antibiotics, Efflux, Membrane biology, Biopharmaceutical, Medication

WESTON, Fla., July 15, 2021 /PRNewswire/ --ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium.

Key Points: 
  • WESTON, Fla., July 15, 2021 /PRNewswire/ --ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium.
  • Mr. Glover's presentation will highlight progress in advancing development of inflammasome inhibitor, IC 100, and cholesterol efflux mediator, VAR 200.
  • For information about ZyVersa's inflammasome inhibitor and cholesterol efflux mediator, visit www.ZyVersa.com .
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.

Novel Anti-Cancer Drugs Permeate the Marketplace

Retrieved on: 
Tuesday, May 25, 2021
Clinical medicine, Medicine, Medical specialties, ATP-binding cassette transporters, P-glycoprotein, Oncology, Efflux, Drug resistance, Chemotherapy

P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.

Key Points: 
  • P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.
  • A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity.
  • Sunshine Biopharma's P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs.
  • Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated.

Novel Anti-Cancer Drugs Permeate the Marketplace

Retrieved on: 
Tuesday, May 25, 2021
Clinical medicine, Medicine, Medical specialties, ATP-binding cassette transporters, P-glycoprotein, Oncology, Efflux, Drug resistance, Chemotherapy

P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.

Key Points: 
  • P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.
  • A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity.
  • Sunshine Biopharma's P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs.
  • Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated.

Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Retrieved on: 
Tuesday, May 25, 2021
Clinical medicine, Medicine, Medical specialties, ATP-binding cassette transporters, Oncology, P-glycoprotein, Cancer, Chemotherapy, Drug resistance, Lung cancer, Efflux

P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.

Key Points: 
  • P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types.
  • Sunshine Biopharmas P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs.
  • Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated.
  • Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in the 39th Annual J.P. Morgan Healthcare Conference 2021, January 11th - 14th

Retrieved on: 
Wednesday, January 6, 2021
Branches of biology, Cytokines, Inflammasome, Efflux, Pharmaceutical industry, Life sciences, Biology

To learn more about ZyVersa and its novel inflammasome inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease, please schedule a virtual meeting with ZyVersa using the conference's BIO One-on-One Partnering System Click Here .

Key Points: 
  • To learn more about ZyVersa and its novel inflammasome inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease, please schedule a virtual meeting with ZyVersa using the conference's BIO One-on-One Partnering System Click Here .
  • Meet with ZyVersa at 39th Annual J.P. Morgan Healthcare Conference to learn about novel inflammasome inhibitor IC 100
    The J.P. Morgan Healthcare Conference is Wall Street's premier investor conference focused exclusively on companies defining the healthcare industry.
  • It is the largest and most informative healthcare investment symposium in the industry.
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.

OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

Retrieved on: 
Wednesday, September 30, 2020
Medical specialties, Branches of biology, Clinical medicine, Pathogenic bacteria, Healthcare-associated infections, Carbapenem, Moraxellaceae, Pseudomonadales, Drug resistance, Efflux, Acinetobacter, Porin

Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.

Key Points: 
  • Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.
  • Curetis role during the collaborative research project is to provide research on innovative detection methods for carbapenem resistance based on porin loss and efflux pump overexpression.
  • Resistance is often conferred by mechanisms such as porin loss or efflux pump overexpression, not adequately covered by current diagnostics.
  • This press release includes statements regarding the receipt of a grant from the German government by Curetis GmbH.

TAXIS Pharmaceuticals Announces CARB-X Award of $3.2 Million, With Potential for an Additional $11.4 Million, to Develop Efflux Pump Inhibitors (EPIs), a New Drug Class to Defeat Multi-Drug Resistant Infections

Retrieved on: 
Tuesday, January 14, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Bacteria, Medicine, Medical specialties, Gram-negative bacteria, Antibiotic-resistant bacteria, Pseudomonadales, Antibiotics, Beta-lactamase, Pseudomonas aeruginosa, Drug resistance, Efflux, Carbapenem

EPIs have the potential to resurrect the therapeutic activity of antibiotics that no longer work against MDR P. aeruginosa bacterial infections.

Key Points: 
  • EPIs have the potential to resurrect the therapeutic activity of antibiotics that no longer work against MDR P. aeruginosa bacterial infections.
  • TAXIS Pharmaceuticals is also eligible for additional funding of up to $11.4 million if certain milestones are met.
  • Specifically, TAXIS Pharmaceuticals EPI drug development program targets MDR P. aeruginosa with an emphasis on extended-spectrum beta-lactamase (ESBL) pathogens, including hospital acquired and ventilator associated infections.
  • Efflux Pump Inhibitors (EPIs) represent a new anti-resistance drug class against Gram-negative MDR pathogens.